- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04633395
Treating Pregnancy Related Insomnia With Music
November 3, 2022 updated by: University of Aarhus
Treating Pregnancy Related Insomnia With Music: a Randomised Control Trial
This study aims to examine the effects of 4 weeks music listening at bedtime on sleep quality during the third trimester of pregnancy.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
50-60% of pregnant women suffer from insomnia during pregnancy.
Pregnancy-related insomnia is often neglected due to a lack of suitable and safe treatments.
This study aims to evaluate the effectiveness of music compared to sleep hygiene on sleep quality in a population of first-time pregnant women in the final stages of pregnancy.
A post pregnancy follow-up will be completed to test if potential effects of the treatment might last into early motherhood (1-3 months postpartum).
Study Type
Interventional
Enrollment (Actual)
106
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Aarhus, Denmark, 8000
- Center for Music In the Brain, Aarhus University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Female, aged 18 years or above, pregnant non-mothers
- Have a sufficient level of Danish (verbal) to understand and respond to the questions and task instructions
- Pregnant women will be enrolled in gestation week 29.
Exclusion Criteria:
- Postnatal depression, i.e. a score of 12 or above on the EPDS questionnaire
- Comorbid psychiatric disorder (i.e. epilepsy and depression)
- Using sleep medication
- Working more than two night shifts per week
- History of sleep disorders
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Music before bedtime
Participants will be listening to music before bedtime for a duration of up to 1 hour each night, in a total treatment period of 4 weeks.
Participants will also receive the sleep hygiene guidelines, and be told to follow these.
|
The participant can choose between 5 different soothing playlists
These are behavioural guidelines to help establish a better sleep pattern
|
Active Comparator: Sleep hygiene
Participants will be given sleep hygiene guidelines, and be asked to follow these during the total treatment period of 4 weeks.
|
These are behavioural guidelines to help establish a better sleep pattern
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sleep quality
Time Frame: Change from baseline to the end of the 4-week intervention, (post-treatment data will be collected immediately after completion of intervention). Furthermore, between group differences at follow up, up to 3 months postpartum
|
Pittsburgh Sleep Quality Index.
Scoring from 0-21 with higher numbers meaning more severe sleep problems.
Cut-off score at 5.
|
Change from baseline to the end of the 4-week intervention, (post-treatment data will be collected immediately after completion of intervention). Furthermore, between group differences at follow up, up to 3 months postpartum
|
Sleep quality - insomnia symptoms
Time Frame: Change from baseline to the end of the 4-week intervention, (post-treatment data will be collected immediately after completion of intervention). Furthermore, between group differences at follow up, up to 3 months postpartum
|
Insomnia Severity Index.
A 5-point Likert scale is used to rate each item (e.g., 0 = no problem; 4 = very severe problem), yielding a total score ranging from 0 to 28.
The total score is interpreted as follows: absence of insomnia (0-7); sub-threshold insomnia (8-14); moderate insomnia (15-21); and severe insomnia (22-28).
|
Change from baseline to the end of the 4-week intervention, (post-treatment data will be collected immediately after completion of intervention). Furthermore, between group differences at follow up, up to 3 months postpartum
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Depressive symptoms
Time Frame: Change from baseline to the end of the 4-week intervention, (post-treatment data will be collected immediately after completion of intervention). Furthermore, between group differences at follow up, up to 3 months postpartum
|
Edinburgh Postnatal Depression Scale.
Maximum score of 30, and minimum of 0. The higher the score, the more severe the symptoms.
A Danish cut-off score at 11 is used.
|
Change from baseline to the end of the 4-week intervention, (post-treatment data will be collected immediately after completion of intervention). Furthermore, between group differences at follow up, up to 3 months postpartum
|
Stress
Time Frame: Change from baseline to the end of the 4-week intervention, (post-treatment data will be collected immediately after completion of intervention). Furthermore, between group differences at follow up, up to 3 months postpartum
|
Perceived Stress Scale.
Individual scores on the PSS can range from 0 to 40 with higher scores indicating higher perceived stress.
Scores ranging from 0-13 would be considered low stress.
Scores ranging from 14-26 would be considered moderate stress.
Scores ranging from 27-40 would be considered high perceived stress.
|
Change from baseline to the end of the 4-week intervention, (post-treatment data will be collected immediately after completion of intervention). Furthermore, between group differences at follow up, up to 3 months postpartum
|
Pre-sleep arousal
Time Frame: Change from baseline to the end of the 4-week intervention, (post-treatment data will be collected immediately after completion of intervention). Furthermore, between group differences at follow up, up to 3 months postpartum
|
The Pre-Sleep Arousal Scale (PSAS) contains 16 items with eight symptoms of cognitive (e.g., intrusive thoughts) and eight symptoms of somatic (e.g., sweating) arousal experienced at bed- time.
A total score from 8 to 40 is computed for both subscales with higher scores indicating higher arousal.
|
Change from baseline to the end of the 4-week intervention, (post-treatment data will be collected immediately after completion of intervention). Furthermore, between group differences at follow up, up to 3 months postpartum
|
Prenatal attachment
Time Frame: Change from baseline to the end of the 4-week intervention, (post-treatment data will be collected immediately after completion of intervention). Furthermore, between group differences at follow up, up to 3 months postpartum
|
Prenatal attachment Inventory.
It consists of 21 Likert-type items with a 4-point response scale (1 = almost never, 2 = sometimes, 3 = often, 4 = almost always).
Total scores can range from 21 to 84, with high scores indicating higher levels of prenatal attachment.
|
Change from baseline to the end of the 4-week intervention, (post-treatment data will be collected immediately after completion of intervention). Furthermore, between group differences at follow up, up to 3 months postpartum
|
Anxiety
Time Frame: Change from baseline to the end of the 4-week intervention, (post-treatment data will be collected immediately after completion of intervention). Furthermore, between group differences at follow up, up to 3 months postpartum
|
State- Trait Anxiety Inventory.
It consists of two subtests - trait and state anxiety.
Range of scores for each subtest is 20-80, the higher score indicating greater anxiety.
|
Change from baseline to the end of the 4-week intervention, (post-treatment data will be collected immediately after completion of intervention). Furthermore, between group differences at follow up, up to 3 months postpartum
|
Postpartum bonding
Time Frame: Between group differences at follow up, up to 3 months postpartum
|
Postpartum Bonding Questionnaire.
The PBQ consists of 25 statements about mothers' feelings, where mothers answer how well the statement applies to them on a six-point scales ranging from 0 to 5, with higher values indicating more problems.
Min.
score: 0, Max score: 125
|
Between group differences at follow up, up to 3 months postpartum
|
Childbirth experience
Time Frame: Between group differences at follow up, up to 3 months postpartum
|
Childbirth Experience Questionnaire.
For 19 of the items the response format is a 4-point Likert Scale whereas the last three items use a visual analogue scale (VAS).
The scoring range is 1 to 4 where higher ratings reflect more positive experiences.
Min = 22.
Max = 88
|
Between group differences at follow up, up to 3 months postpartum
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sleep apnea
Time Frame: Pre- and post treatment (at the end date of the 4 week intervention) measurements to ensure the participant has not developed sleep apnea
|
Epworth Sleepiness Scale.
8 items scored from 0-3.
Interpretation: 0-5 lower normal daytime sleepiness.
6-10 normal daytime sleepiness.
11-12 mild excessive daytime symptoms.
13-15 moderate excessive daytime symptoms.
16-24 severe excessive daytime symptoms.
|
Pre- and post treatment (at the end date of the 4 week intervention) measurements to ensure the participant has not developed sleep apnea
|
Music reward
Time Frame: Baseline measurement only.
|
Barcelona Music Reward Questionnaire.
The BMRQ is a 20-item questionnaire that examines five main facets that characterize musical reward experience in individuals: musical seeking, emotion evocation, mood regulation, social reward and sensory-motor.
Participants indicate the level of agreement with each statement by using a five-point scale ranging from "fully disagree" (1) to "fully agree" (5).
The contribution of each facet to the overall music reward experience is quantified by a numerical value obtained upon completion of the survey.
A score for global sensitivity to music reward is also provided, which was obtained as the weighted sum of participants' scores (i.e., factor score).
The mean value of each factor is 50, and the standard deviation is 10.
Standard values are therefore located between 40 and 60.
Punctuations below 40 indicate low values in this particular facet, whereas values above 60 indicate high values (the same applies to the global sensitivity to music reward)
|
Baseline measurement only.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Morten L Kringelbach, Professor, Aarhus University anf University of Oxford
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 1, 2020
Primary Completion (Actual)
August 30, 2022
Study Completion (Actual)
August 30, 2022
Study Registration Dates
First Submitted
November 3, 2020
First Submitted That Met QC Criteria
November 17, 2020
First Posted (Actual)
November 18, 2020
Study Record Updates
Last Update Posted (Actual)
November 4, 2022
Last Update Submitted That Met QC Criteria
November 3, 2022
Last Verified
May 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Caregiving+
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Insomnia
-
Leiden UniversityBioClock Consortium; Caring UniveristiesCompleted
-
National Science Council, TaiwanCompleted
-
Sunshine Lake Pharma Co., Ltd.Unknown
-
Pfizer's Upjohn has merged with Mylan to form Viatris...Completed
-
Massachusetts General HospitalNational Institutes of Health (NIH)Completed
-
IpsenCompletedThe Effectiveness of Circadin in Improving Quality of Sleep in Patients Aged 55 or Over (QUALISLEEP)InsomniaRussian Federation
-
Charite University, Berlin, GermanyCompleted
-
Roxane LaboratoriesCompleted
-
Butler HospitalSunovionCompleted
Clinical Trials on Music
-
Azad University of Medical SciencesCompleted
-
Ankara Diskapi Training and Research HospitalCompleted
-
The University of Texas Health Science Center at...Active, not recruiting
-
Assistance Publique - Hôpitaux de ParisUnknown
-
Corporacion Parc TauliRecruitingDistal Radius Fracture ReductionSpain
-
Ankara Diskapi Training and Research HospitalCompleted
-
University Hospital, LimogesUnknown
-
Western University, CanadaNot yet recruitingPatient Satisfaction
-
Christiana Care Health ServicesCompleted